|
NZ250844A
(en)
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
DK0966297T4
(da)
|
1996-08-08 |
2013-03-18 |
Amylin Pharmaceuticals Llc |
Regulering af gastrointestinal motilitet
|
|
PT944648E
(pt)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk As |
Derivados do glp-1.
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
ES2247676T3
(es)
|
1997-01-07 |
2006-03-01 |
Amylin Pharmaceuticals, Inc. |
Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
PT1019077E
(pt)
|
1997-08-08 |
2008-02-21 |
Amylin Pharmaceuticals Inc |
Novos compostos agonistas de exendina
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
NZ504258A
(en)
|
1997-11-14 |
2002-12-20 |
Amylin Pharmaceuticals Inc |
Exendin 3 and 4 agonist compounds for the treatment of diabetes
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
BR9814189A
(pt)
|
1997-11-14 |
2000-10-03 |
Amylin Pharmaceuticals Inc |
"compostos agonistas da exendina"
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
JP4353544B2
(ja)
|
1998-01-09 |
2009-10-28 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
アミリン作動薬ペプチド用製剤
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
NZ506839A
(en)
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
WO1999047160A1
(en)
|
1998-03-13 |
1999-09-23 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
SK19042000A3
(sk)
|
1998-06-12 |
2001-11-06 |
Bionebraska, Inc. |
Glukagónu podobný peptid-1 zlepšujúci odpoveď beta-bunkiek na glukózu u subjektov so zhoršenou toleranciou glukózy
|
|
EP1105460B1
(en)
|
1998-08-10 |
2009-10-07 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
|
|
CN1317967A
(zh)
|
1998-09-17 |
2001-10-17 |
伊莱利利公司 |
蛋白质制剂
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
ES2249933T3
(es)
|
1998-12-22 |
2006-04-01 |
Eli Lilly And Company |
Formulacion autoestable de peptido 1 tipo glucagon.
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
CA2356331C
(en)
|
1999-01-14 |
2009-10-13 |
Amylin Pharmaceuticals, Inc. |
Methods for glucagon suppression
|
|
NZ512663A
(en)
|
1999-01-14 |
2004-05-28 |
Amylin Pharmaceuticals Inc |
Novel exendin agonist formulations and methods of administration thereof
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
CN1344248A
(zh)
|
1999-03-17 |
2002-04-10 |
诺沃挪第克公司 |
肽的酰化方法和新酰化剂
|
|
EP1175443A1
(en)
|
1999-04-30 |
2002-01-30 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
WO2000069911A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
DE60105547T3
(de)
|
2000-01-10 |
2014-12-31 |
Amylin Pharmaceuticals, Llc |
Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
|
|
CA2402733A1
(en)
|
2000-03-14 |
2001-09-20 |
Burkhard Goke |
Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
|
|
CA2380423A1
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
|
CN1462191B
(zh)
|
2000-05-19 |
2013-07-24 |
埃米林药品公司 |
Glp-1用于制备治疗急性冠脉综合征的药物的用途
|
|
JP4624642B2
(ja)
|
2000-08-18 |
2011-02-02 |
エミスフェアー・テクノロジーズ・インク |
活性剤デリバリー用化合物および組成物
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
MXPA02006118A
(es)
|
2000-10-20 |
2004-08-23 |
Amylin Pharmaceuticals Inc |
Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1.
|
|
HU230603B1
(hu)
|
2000-12-07 |
2017-03-28 |
Eli Lilly And Company |
GLP1 fúziós fehérjék
|
|
AU2002239384B2
(en)
|
2000-12-13 |
2007-01-11 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
JP2005506956A
(ja)
|
2001-06-01 |
2005-03-10 |
イーライ・リリー・アンド・カンパニー |
長時間作用性ｇｌｐ−１製剤
|
|
DE60224284T2
(de)
|
2001-06-28 |
2008-12-18 |
Novo Nordisk A/S |
Stabile formulierung von modifiziertem glp-1
|
|
JP3935487B2
(ja)
|
2001-07-16 |
2007-06-20 |
フーベルト・ケスター |
捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
|
|
EP1411968B1
(en)
|
2001-07-31 |
2008-09-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Glp-1 exendin-4 peptide analogs and uses thereof
|
|
JP2005508895A
(ja)
|
2001-08-28 |
2005-04-07 |
イーライ・リリー・アンド・カンパニー |
Ｇｌｐ−１および基礎インスリンの予備混合物
|
|
CN1571676A
(zh)
|
2001-10-19 |
2005-01-26 |
伊莱利利公司 |
Glp－1和胰岛素的双相混合物
|
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
WO2003059934A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
KR20040085205A
(ko)
|
2002-02-20 |
2004-10-07 |
일라이 릴리 앤드 캄파니 |
Ｇｌｐ-1 분자의 투여 방법
|
|
AU2003219958B2
(en)
|
2002-02-27 |
2006-01-05 |
Immunex Corporation |
Polypeptide formulation
|
|
ATE421088T1
(de)
|
2002-03-11 |
2009-01-15 |
Caprotec Bioanalytics Gmbh |
Verbindungen und verfahren für die analyse des proteoms
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
AU2003226913A1
(en)
|
2002-04-04 |
2003-10-20 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
AU2003232172A1
(en)
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
|
CN1665540A
(zh)
|
2002-07-09 |
2005-09-07 |
桑多斯股份公司 |
含1,2－丙二醇的高浓度人生长激素液体制剂
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
EP2409686A1
(en)
|
2002-08-01 |
2012-01-25 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
US8372804B2
(en)
|
2007-10-24 |
2013-02-12 |
Mannkind Corporation |
Delivery of active agents
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
EP2058311A3
(de)
|
2002-08-21 |
2011-04-13 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
8-[3-amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
JP2006517908A
(ja)
|
2002-10-02 |
2006-08-03 |
ジーランド・ファーマ・ア／エス |
安定化したエキセンディン−４化合物
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
SI1583541T1
(sl)
|
2002-11-20 |
2011-08-31 |
Neuronova Ab |
Spojine in postopki za povečanje nevrogeneze
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
WO2004056313A2
(en)
|
2002-12-17 |
2004-07-08 |
Amylin Pharmaceuticals, Inc. |
Prevention and treatment of cardiac arrhythmias
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
WO2004089280A2
(en)
|
2003-04-08 |
2004-10-21 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
WO2004103390A2
(en)
|
2003-05-15 |
2004-12-02 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
WO2005000360A2
(en)
|
2003-05-23 |
2005-01-06 |
Nektar Therapeutics Al, Corporation |
Peg derivatives having an amidocarbonate linkage
|
|
US8008255B2
(en)
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
JP2007524592A
(ja)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
WO2004105781A2
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
EP2292253A3
(en)
|
2003-06-03 |
2011-12-14 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
JP4936884B2
(ja)
|
2003-06-03 |
2012-05-23 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
WO2005012347A2
(en)
|
2003-08-05 |
2005-02-10 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
AU2004266757A1
(en)
|
2003-08-21 |
2005-03-03 |
Novo Nordisk A/S |
Separation of polypeptides comprising a racemized amino acid
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
|
ES2373660T3
(es)
|
2003-11-13 |
2012-02-07 |
Novo Nordisk A/S |
Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
EP3300721B1
(en)
|
2003-11-20 |
2019-03-06 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
|
EP1750752A2
(en)
|
2003-11-20 |
2007-02-14 |
Neuronova AB |
Compounds and methods for increasing neurogenesis
|
|
JP5697831B2
(ja)
|
2003-12-03 |
2015-04-08 |
ノヴォ ノルディスク アー／エス |
単鎖インシュリン
|
|
WO2005058366A2
(en)
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
AU2005320351B2
(en)
|
2004-02-11 |
2010-06-03 |
Amylin Pharmaceuticals, Llc |
Amylin family peptides and methods for making and using them
|
|
WO2006066024A2
(en)
|
2004-12-13 |
2006-06-22 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
KR20120034237A
(ko)
|
2004-02-11 |
2012-04-10 |
아밀린 파마슈티칼스, 인크. |
선택가능한 특성을 갖는 하이브리드 폴리펩티드
|
|
CA2555894A1
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
KR101040415B1
(ko)
|
2004-04-15 |
2011-06-09 |
알케르메스,인코포레이티드 |
중합체 기재 지속적 방출 방법
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
EP2316446A1
(en)
|
2004-06-11 |
2011-05-04 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
|
US7534763B2
(en)
*
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
|
PT1773878E
(pt)
|
2004-07-19 |
2015-06-05 |
Biocon Ltd |
Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
|
|
BRPI0512396A
(pt)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
|
MX2007001424A
(es)
|
2004-08-03 |
2008-03-13 |
Biorexis Pharmaceutical Corp |
Terapia de combinacion usando proteinas de fusion a transferrina que comprenden peptido 1 tipo glucagon.
|
|
EP1789434B1
(en)
|
2004-08-31 |
2013-11-20 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
EP1791554A2
(en)
|
2004-09-17 |
2007-06-06 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
|
US7906136B2
(en)
|
2004-10-01 |
2011-03-15 |
Ramscor, Inc. |
Conveniently implantable sustained release drug compositions
|
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー／エス |
遅延性のエキセンディン−４化合物
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
WO2006044531A2
(en)
|
2004-10-13 |
2006-04-27 |
Isis Parmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
CN101056650A
(zh)
|
2004-11-12 |
2007-10-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
EP1814581B1
(en)
|
2004-11-12 |
2016-03-16 |
Novo Nordisk A/S |
Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
|
|
JP5175103B2
(ja)
|
2004-11-12 |
2013-04-03 |
ノヴォ ノルディスク アー／エス |
安定なペプチド製剤
|
|
AU2005311099B2
(en)
|
2004-12-02 |
2012-02-02 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
|
|
ES2357089T5
(es)
|
2004-12-21 |
2014-02-24 |
Nektar Therapeutics |
Reactivos de tiol polimérico estabilizados
|
|
UA87009C2
(ru)
|
2004-12-22 |
2009-06-10 |
Эли Лилли Энд Компани |
Композиции, которые содержат гибридные белки-аналоги glp-1
|
|
CA2599594A1
(en)
|
2004-12-24 |
2006-07-13 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
JP4785206B2
(ja)
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
|
|
EP1848541A4
(en)
|
2005-02-07 |
2013-01-16 |
Pharmalight Inc |
METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
US20090286723A1
(en)
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
|
EP2390264A1
(en)
|
2005-02-11 |
2011-11-30 |
Amylin Pharmaceuticals Inc. |
GIP analog and hybrid polypeptides with selectable propperties
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
WO2006110887A2
(en)
|
2005-04-11 |
2006-10-19 |
Amylin Pharmaceuticals, Inc |
Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
|
|
JP4979686B2
(ja)
|
2005-04-24 |
2012-07-18 |
ノボ・ノルデイスク・エー／エス |
注入デバイス
|
|
EP1888118B1
(en)
|
2005-05-25 |
2016-08-17 |
Novo Nordisk A/S |
Polypeptide formulations stabilized with ethylenediamine
|
|
CN101217940B
(zh)
|
2005-06-06 |
2013-03-27 |
卡穆鲁斯公司 |
Glp-1类似物制剂
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
ATE553124T1
(de)
|
2005-06-13 |
2012-04-15 |
Imp Innovations Ltd |
Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
|
|
ES2536450T3
(es)
|
2005-06-16 |
2015-05-25 |
Nektar Therapeutics |
Conjugados que tienen una unión degradable y reactivos poliméricos útiles en la preparación de tales conjugados
|
|
US20070092482A1
(en)
|
2005-08-04 |
2007-04-26 |
Bossard Mary J |
Conjugates of a G-CSF moiety and a polymer
|
|
US8278420B2
(en)
|
2005-08-06 |
2012-10-02 |
Qinghua Wang |
Composition and method for prevention and treatment of type I diabetes
|
|
CN105056211A
(zh)
|
2005-08-19 |
2015-11-18 |
安米林药品有限责任公司 |
治疗糖尿病和降低体重的毒蜥外泌肽
|
|
RU2390325C2
(ru)
|
2005-09-14 |
2010-05-27 |
Маннкайнд Корпорейшн |
Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
|
|
JP5072848B2
(ja)
|
2005-09-20 |
2012-11-14 |
ノバルティス アーゲー |
低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
|
|
US8759290B2
(en)
|
2005-10-18 |
2014-06-24 |
Biocon Limited |
Oral glucagon-like peptide conjugates for metabolic diseases
|
|
US20070099820A1
(en)
|
2005-10-19 |
2007-05-03 |
Smartcells, Inc. |
Polymer-drug conjugates
|
|
ES2572952T3
(es)
|
2005-11-07 |
2016-06-03 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
|
WO2007053946A1
(en)
|
2005-11-09 |
2007-05-18 |
Conjuchem Biotechnologies Inc. |
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
|
CA2632903C
(en)
|
2005-12-02 |
2015-11-24 |
Vianova Labs, Inc. |
Treatment of cancer and other diseases
|
|
BRPI0620586A2
(pt)
|
2005-12-02 |
2011-11-16 |
Nastech Pharm Co |
formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento
|
|
US20080318861A1
(en)
|
2005-12-08 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Mucosal Delivery of Stabilized Formulations of Exendin
|
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
WO2007073486A2
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
SI1984009T1
(sl)
|
2006-01-18 |
2013-02-28 |
Qps, Llc |
Farmacevtski sestavki z izboljĺ ano stabilnostjo
|
|
CA2638811A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
EP2004238A2
(en)
|
2006-03-21 |
2008-12-24 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
JP2009533460A
(ja)
|
2006-04-13 |
2009-09-17 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
ｈＧＬＰ−１、エクセンジン−４およびその類似体の医薬組成物
|
|
RU2409349C2
(ru)
|
2006-04-14 |
2011-01-20 |
Маннкайнд Корпорейшн |
Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
|
|
DE202006006388U1
(de)
|
2006-04-20 |
2007-08-30 |
Tegometall (International) Ag |
Regal-Fachboden
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
WO2007133778A2
(en)
|
2006-05-12 |
2007-11-22 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
EA200870575A1
(ru)
|
2006-05-26 |
2009-08-28 |
Амилин Фармасьютикалз, Инк. |
Композиции и способы лечения застойной сердечной недостаточности
|
|
US20100022457A1
(en)
*
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
PL2038423T3
(pl)
|
2006-06-21 |
2013-05-31 |
Biocon Ltd |
Metoda wytwarzania biologicznie aktywnego polipeptydu insulinotropowego
|
|
WO2008038147A2
(en)
|
2006-07-05 |
2008-04-03 |
Foamix Ltd. |
Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
|
|
JP5102833B2
(ja)
|
2006-07-24 |
2012-12-19 |
バイオレクシス ファーマシューティカル コーポレーション |
エキセンディン融合タンパク質
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
US20090325860A1
(en)
|
2006-08-04 |
2009-12-31 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
PT2359808E
(pt)
|
2006-08-09 |
2013-08-28 |
Intarcia Therapeutics Inc |
Sistemas de entrega osmótica e montagens de pistão
|
|
AU2007284365A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
EP2057189B1
(en)
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
CN101125207B
(zh)
|
2006-11-14 |
2012-09-05 |
上海华谊生物技术有限公司 |
带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
|
|
EP2124883A2
(en)
|
2006-12-12 |
2009-12-02 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations and methods for making the same
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
CN101663317A
(zh)
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
ES2628063T3
(es)
|
2007-01-05 |
2017-08-01 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
|
|
US20090098130A1
(en)
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
GEP20135944B
(en)
|
2007-02-15 |
2013-10-25 |
Indiana Unversity Research And Tech Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
RU2440097C2
(ru)
|
2007-04-23 |
2012-01-20 |
Интарсия Терапьютикс, Инк. |
Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
|
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
WO2008148839A2
(en)
|
2007-06-08 |
2008-12-11 |
Ascendis Pharma As |
Long-acting polymeric prodrugs of exendin
|
|
DK2158214T3
(da)
|
2007-06-15 |
2011-12-05 |
Zealand Pharma As |
Glukagonanaloger
|
|
NZ582480A
(en)
|
2007-07-10 |
2011-03-31 |
Lilly Co Eli |
Glp-1-fc fusion protein formulation
|
|
EP2185178B1
(en)
|
2007-08-03 |
2017-08-23 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
EP2570431A3
(en)
|
2007-08-30 |
2013-05-01 |
CureDM Group Holdings, LLC |
Compositions and methods of using proislet peptides and analogs thereof
|
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
WO2009035540A2
(en)
|
2007-09-07 |
2009-03-19 |
Ipsen Pharma S.A.S. |
Analogues of exendin-4 and exendin-3
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
EP2211842B1
(en)
|
2007-10-24 |
2015-08-12 |
MannKind Corporation |
An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
|
|
EP2214691B1
(en)
|
2007-10-30 |
2015-09-30 |
Indiana University Research and Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
AU2008318986B2
(en)
|
2007-10-30 |
2014-12-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
|
BRPI0820535B8
(pt)
|
2007-11-16 |
2021-05-25 |
Novo Nordisk As |
composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
|
|
EP2224945B1
(en)
|
2007-11-23 |
2012-05-16 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
US20090186819A1
(en)
|
2007-12-11 |
2009-07-23 |
Marieve Carrier |
Formulation of insulinotropic peptide conjugates
|
|
JP2011511778A
(ja)
|
2008-01-30 |
2011-04-14 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
エステルに基づいたペプチドプロドラッグ
|
|
RU2010136023A
(ru)
|
2008-02-01 |
2012-03-10 |
Асцендис Фарма Ас (Dk) |
Пролекарство, содержащее саморасщепляемый линкер
|
|
MX2010008654A
(es)
|
2008-02-06 |
2010-10-06 |
Biocon Ltd |
Medios de fermentacion y procedimientos para los mismos.
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
US20110034385A1
(en)
|
2008-04-07 |
2011-02-10 |
National Institute Of Immunology |
Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder
|
|
KR20110007242A
(ko)
|
2008-05-07 |
2011-01-21 |
메리온 리서치 Ⅲ 리미티드 |
펩티드 조성물 및 그의 제조 방법
|
|
EP2303313B1
(en)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendins to lower cholestrol and triglycerides
|
|
JP2011523052A
(ja)
|
2008-05-23 |
2011-08-04 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
CN101827626B
(zh)
|
2008-06-13 |
2015-03-18 |
曼金德公司 |
干粉吸入器和用于药物输送的系统
|
|
RU2560254C2
(ru)
|
2008-06-17 |
2015-08-20 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ И СТАБИЛЬНОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМИ ЗНАЧЕНИЯМИ Ph
|
|
EA019203B9
(ru)
|
2008-06-17 |
2014-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты глюкагонового рецептора/glp-1-рецептора
|
|
CN104945500B
(zh)
|
2008-06-17 |
2019-07-09 |
印第安纳大学研究及科技有限公司 |
基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
|
|
CA2727147A1
(en)
|
2008-06-17 |
2009-12-23 |
Otsuka Chemical Co., Ltd. |
Glycosylated glp-1 peptide
|
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
EP2303247A4
(en)
|
2008-07-21 |
2012-08-01 |
Syneron Medical Ltd |
TRANSDERMALES SYSTEM FOR THE EXTENDED RELEASE OF INCRETINS AND INCRETIN MIMETIC PEPTIDES
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
BRPI0920881B1
(pt)
|
2008-10-17 |
2021-09-21 |
Sanofi-Aventis Deutschland Gmbh |
Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
|
|
SI2373681T1
(sl)
|
2008-12-10 |
2017-05-31 |
Glaxosmithkline Llc Corporation Service Company |
Farmacevtski sestavki albiglutida
|
|
WO2010070253A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AU2008365559B2
(en)
|
2008-12-15 |
2016-02-25 |
Zealand Pharma A/S |
Glucagon analogues
|
|
BRPI0823378A2
(pt)
|
2008-12-15 |
2019-09-24 |
Zealand Pharma As |
análogos de glucagon
|
|
EA020520B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
|
AR074811A1
(es)
|
2008-12-19 |
2011-02-16 |
Univ Indiana Res & Tech Corp |
Profarmaco de peptido de la superfamilia de glucagon basados en amida
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
MX2011009251A
(es)
|
2009-03-04 |
2011-11-18 |
Mannkind Corp |
Sistema mejorado de suministro de farmaco en polvo seco.
|
|
JP5608686B2
(ja)
|
2009-03-05 |
2014-10-15 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
後退可能な針を備えた薬物送達デバイス
|
|
WO2010120476A2
(en)
|
2009-04-01 |
2010-10-21 |
Amylin Pharmaceuticals, Inc. |
N-terminus conformationally constrained glp-1 receptor agonist compounds
|
|
US8992886B2
(en)
|
2009-04-06 |
2015-03-31 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
EP2423233B1
(en)
|
2009-04-22 |
2015-03-11 |
Alteogen, Inc |
In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
JP5698223B2
(ja)
|
2009-05-20 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
薬物送達デバイスにおける薬物含有カートリッジ用の栓
|
|
EP3189868B1
(en)
|
2009-05-20 |
2024-10-23 |
Sanofi-Aventis Deutschland GmbH |
A bung for drug containing cartridges in drug delivery devices comprising an electronic coding feature
|
|
WO2010138671A1
(en)
|
2009-05-28 |
2010-12-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
CN102802657A
(zh)
|
2009-06-11 |
2012-11-28 |
诺沃-诺迪斯克有限公司 |
用于治疗2型糖尿病的glp-1和fgf21组合
|
|
US9150632B2
(en)
|
2009-06-16 |
2015-10-06 |
Indiana University Research And Technology Corporation |
GIP receptor-active glucagon compounds
|
|
EP2448965A4
(en)
|
2009-07-02 |
2015-02-11 |
Angiochem Inc |
MULTIMEPEPTID CONJUGATES AND ITS USES
|
|
PT2454282E
(pt)
|
2009-07-13 |
2015-06-23 |
Zealand Pharma As |
Análogos de glucagão acilados
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
BR112012002168A2
(pt)
|
2009-07-31 |
2016-05-31 |
Sanofi Aventis Deutschland |
profármacos compreendendo um conjugado ligador de insulina
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
AU2010303112A1
(en)
|
2009-09-30 |
2012-04-26 |
Glaxo Group Limited |
Drug fusions and conjugates with extended half life
|
|
DK2490708T3
(da)
|
2009-10-22 |
2013-04-15 |
Biodel Inc |
Stabiliserede glucagon-opløsninger
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
BR112012011467A2
(pt)
|
2009-10-30 |
2019-09-24 |
Otsuka Chemical Co Ltd |
forma glicosilada de análogo ao glp-1 antigênico.
|
|
US20120294855A1
(en)
|
2009-11-03 |
2012-11-22 |
Eli Lilly & Company |
Glp-1 receptor agonist compounds for obstructive sleep apnea
|
|
DK2554183T3
(en)
|
2009-11-13 |
2018-07-23 |
Sanofi Aventis Deutschland |
A pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
|
|
TWI468171B
(zh)
|
2009-11-13 |
2015-01-11 |
Sanofi Aventis Deutschland |
含ｇｌｐ－１激動劑及甲硫胺酸之醫藥組成物
|
|
KR20120092714A
(ko)
|
2009-12-15 |
2012-08-21 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
비만 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
|
|
CN102753170A
(zh)
|
2009-12-15 |
2012-10-24 |
新陈代谢解决方案开发公司 |
治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合
|
|
EP3202401B1
(en)
|
2009-12-15 |
2019-10-23 |
Cirius Therapeutics, Inc. |
Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
|
|
KR102029611B1
(ko)
|
2009-12-15 |
2019-10-07 |
씨리우스 테라퓨틱스, 엘엘씨 |
대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
|
|
JP2013514322A
(ja)
|
2009-12-16 |
2013-04-25 |
ノヴォ ノルディスク アー／エス |
修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
|
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
CN101798588B
(zh)
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
AR079345A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina
|
|
EP2525809B1
(en)
|
2010-01-20 |
2016-08-03 |
Zealand Pharma A/S |
Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions
|
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
|
BR112012019144A2
(pt)
|
2010-02-01 |
2016-10-04 |
Sanofi Aventis Deutschland |
suporte de cartucho, dispositivo de distribuição de fármaco e método para fixação de um cartucho em um suporte de cartucho
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
AU2011231503C1
(en)
|
2010-03-26 |
2016-03-03 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
US9145451B2
(en)
|
2010-05-13 |
2015-09-29 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhbiting G protein coupled receptor activity
|
|
JP6121323B2
(ja)
|
2010-05-13 |
2017-05-10 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
EA201291009A1
(ru)
|
2010-05-20 |
2013-05-30 |
Глаксо Груп Лимитед |
Улучшенные связывающие варианты против сывороточного альбумина
|
|
WO2011156407A2
(en)
|
2010-06-09 |
2011-12-15 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonists to treat pancre-atitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
BR112012033060A2
(pt)
|
2010-06-21 |
2018-02-27 |
Mannkind Corp |
métodos de sistema de liberação de fármaco em pó seco
|
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
KR20130102470A
(ko)
|
2010-06-24 |
2013-09-17 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
|
|
US9234023B2
(en)
|
2010-06-24 |
2016-01-12 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
MX2013001131A
(es)
|
2010-07-28 |
2013-10-17 |
Amylin Pharmaceuticals Llc |
Compuestos agonistas del receptor del peptido similar al glucagon tipo 1 que tienen regiones estabilizadas.
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
CA2812951A1
(en)
|
2010-09-28 |
2012-04-19 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action
|
|
ES2533601T3
(es)
|
2010-11-03 |
2015-04-13 |
Arecor Limited |
Nueva composición que comprende glucagón
|
|
KR101931392B1
(ko)
|
2010-11-09 |
2018-12-20 |
맨카인드 코포레이션 |
세로토닌 수용체 작용제 및 디케토피페라진을 포함하는 편두통 치료용 조성물
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
EP2651398B1
(en)
|
2010-12-16 |
2017-12-13 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
EP2654767A4
(en)
|
2010-12-22 |
2014-05-21 |
Amylin Pharmaceuticals Inc |
GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
|
|
KR20130132931A
(ko)
|
2010-12-22 |
2013-12-05 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체 활성을 나타내는 글루카곤 유사체들
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
EA028572B1
(ru)
|
2011-03-10 |
2017-12-29 |
Ксерис Фармасьютикалс, Инк. |
Стабильная композиция для парентеральной инъекции и способы ее получения и использования
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN102718868A
(zh)
|
2011-03-30 |
2012-10-10 |
上海华谊生物技术有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
DK2694095T3
(en)
|
2011-04-05 |
2018-05-28 |
Longevity Biotech Inc |
COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
|
|
EP2696897A2
(en)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
CA2836574C
(en)
|
2011-05-18 |
2021-11-30 |
Mederis Diabetes, Llc |
Improved peptide pharmaceuticals for insulin resistance
|
|
US20140221282A1
(en)
|
2011-05-25 |
2014-08-07 |
Astrazeneca Pharmaceuticals Lp |
Long duration dual hormone conjugates
|
|
DE102011102879B4
(de)
|
2011-05-31 |
2014-03-27 |
Pewag Schneeketten Gmbh & Co Kg |
Kettenglied für Gleitschutzketten für Fahrzeugreifen, sowie Gleitschutzkette umfassend solche Kettenglieder
|
|
UA113626C2
(xx)
*
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
JP5914641B2
(ja)
|
2011-06-10 |
2016-05-11 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用
|
|
LT2718318T
(lt)
|
2011-06-10 |
2018-10-25 |
Hanmi Science Co., Ltd. |
Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui
|
|
PT2721062T
(pt)
|
2011-06-17 |
2019-02-12 |
Hanmi Science Co Ltd |
Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo
|
|
ES2636445T3
(es)
|
2011-06-22 |
2017-10-05 |
Indiana University Research And Technology Corporation |
Coagonistas de receptores de glucagón/GLP-1
|
|
BR112013032717A2
(pt)
|
2011-06-22 |
2017-01-24 |
Univ Indiana Res & Tech Corp |
coagonistas do receptor de glucagon/glp-1
|
|
US20140220134A1
(en)
|
2011-06-24 |
2014-08-07 |
Astrazeneca Pharamceuticals LP |
Method for treating diabetes with extended release formulation of glp-1 receptor agonists
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
US9382304B2
(en)
|
2011-07-08 |
2016-07-05 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
CA2843586A1
(fr)
|
2011-08-10 |
2013-02-14 |
Adocia |
Solution injectable d'au moins une insuline basale
|
|
WO2013028989A1
(en)
|
2011-08-24 |
2013-02-28 |
Phasebio Pharmaceuticals, Inc. |
Formulations of active agents for sustained release
|
|
WO2013029279A1
(zh)
|
2011-09-03 |
2013-03-07 |
深圳市健元医药科技有限公司 |
新的glp-ⅰ类似物及其制备方法和用途
|
|
TWI596110B
(zh)
|
2011-09-23 |
2017-08-21 |
諾佛 儂迪克股份有限公司 |
新穎升糖素類似物
|
|
IN2014CN02616A
(sl)
|
2011-10-28 |
2015-06-26 |
Sanofi Aventis Deutschland |
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
KR20140097151A
(ko)
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
|
ES2784629T3
(es)
|
2011-11-29 |
2020-09-29 |
Jurox Pty Ltd |
Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
|
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EP2793928B1
(en)
|
2011-12-22 |
2017-03-15 |
Pfizer Inc |
Process for purifying a sample of h38c2 antibody
|
|
AP2014007797A0
(en)
|
2011-12-23 |
2014-07-31 |
Boehringer Ingelheim Int |
Glucagon analogues
|
|
CN104159570A
(zh)
|
2011-12-29 |
2014-11-19 |
陈献 |
稳定的胰高血糖素纳米乳液
|
|
CN113730555A
(zh)
|
2012-01-09 |
2021-12-03 |
阿道恰公司 |
Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
|
|
EP2844269A4
(en)
|
2012-03-28 |
2016-01-06 |
Amylin Pharmaceuticals Llc |
TRANSMUCULOUS ADMINISTRATION OF GENETICALLY MODIFIED POLYPEPTIDES
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US20150111246A1
(en)
|
2012-04-24 |
2015-04-23 |
Astrazeneca Pharmaceuticals Lp |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
MX356958B
(es)
|
2012-05-03 |
2018-06-20 |
Zealand Pharma As |
Análogos de péptido-2 tipo glucagón (glp-2).
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
US20150174209A1
(en)
|
2012-05-25 |
2015-06-25 |
Amylin Pharmaceuticals. Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
WO2013174478A1
(en)
|
2012-05-25 |
2013-11-28 |
Merck Patent Gmbh |
Bimesogenic compounds and mesogenic media
|
|
MX2014015423A
(es)
|
2012-06-14 |
2015-04-09 |
Sanofi Sa |
Analogos de peptido de exedina-4.
|
|
CA2877127A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Analogs of glucagon exhibiting gip receptor activity
|
|
BR112015000529B1
(pt)
|
2012-07-12 |
2022-01-11 |
Mannkind Corporation |
Inalador de pó seco
|
|
MY170671A
(en)
|
2012-07-23 |
2019-08-26 |
Zealand Pharma As |
Glucagon analogues
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
EP2934562A1
(en)
|
2012-08-14 |
2015-10-28 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
WO2014027254A1
(en)
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
US9546205B2
(en)
|
2012-09-17 |
2017-01-17 |
Imperial Innovations Limited |
Peptide analogues of glucagon and GLP1
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
NZ739063A
(en)
|
2012-11-06 |
2019-11-29 |
Hanmi Pharm Ind Co Ltd |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
CN117903257A
(zh)
|
2012-11-20 |
2024-04-19 |
梅德瑞斯糖尿病有限责任公司 |
用于胰岛素抗性的改良的肽药物
|
|
TWI617574B
(zh)
|
2012-12-11 |
2018-03-11 |
梅迪繆思有限公司 |
用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
|
|
EP2934569A1
(en)
|
2012-12-21 |
2015-10-28 |
Sanofi |
Exendin-4 derivatives
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
JP6538645B2
(ja)
|
2013-03-14 |
2019-07-03 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
インスリン‐インクレチン複合物
|
|
CA2902352A1
(en)
|
2013-03-14 |
2014-09-18 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
|
US20160058881A1
(en)
|
2013-03-15 |
2016-03-03 |
Indiana University Research And Technology Corporation |
Prodrugs with prolonged action
|
|
CA2909581A1
(en)
|
2013-04-18 |
2014-10-23 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
SG11201602965WA
(en)
|
2013-10-17 |
2016-05-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
TW201609800A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
|
|
TW201609798A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
Ｅｘｅｎｄｉｎ－４胜肽類似物
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
JP6641280B2
(ja)
|
2014-01-09 |
2020-02-05 |
サノフイＳａｎｏｆｉ |
インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
|
|
WO2015104311A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN106519015B
(zh)
|
2014-09-23 |
2020-04-17 |
深圳市图微安创科技开发有限公司 |
胃泌酸调节素类似物
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|